Kamada is a plasma-derived biopharmaceutical company focused on orphan indications, with an existing marketed product portfolio and a late-stage product pipeline. Co. uses its platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived immune globulins. Co.'s activity is divided into two operating segments: Proprietary Products, which includes the development, manufacturing, sales and distribution of plasma-derived protein therapeutics; and Distribution, which distributes imported drug products in Israel that are manufactured by third parties. We show 12 historical shares outstanding datapoints in our coverage of KMDA's shares outstanding history.
Understanding the changing numbers of KMDA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like KMDA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching KMDA by allowing them to research KMDA shares outstanding history
as well as any other stock in our coverage universe. |
Free KMDA Email Alerts:
Video: Shares Outstanding Importance
